#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology.
Tag: letrozole
Letrozole and abemaciclib in estrogen receptor–positive recurrent endometrial cancer
1. Almost half of patients (47%) had either an objective response or had progression free survival for at least 6 ...
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
Click to read this study in The Lancet Oncology.
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
Click to read this study in JAMA Network Open.
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression
Click to read this study in The Lancet Oncology.
Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
#VisualAbstract: Fulvestrant-palbociclib and letrozole-palbociclib are equally effective for HR⁺ advanced breast cancer
Click here to read this study in JAMA Oncology.
#VisualAbstract: Addition of everolimus to letrozole improves survival in patients with HR⁺ breast cancer and disease progression on tamoxifen
Click to read this study in JAMA Oncology.
#VisualAbstract: Extended letrozole therapy improves disease-free survival in postmenopausal patients with breast cancer
Click to read the study in The Lancet Oncology.
#VisualAbstract: Everolimus plus leuprorelin and letrozole improves progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases
Click to read the study in European Journal of Cancer